-

Vaccines, Blood & Biologics

  • Share Share this page

Investigational New Drug (IND) or Device Exemption (IDE) Process (CBER)

An Investigational New Drug Application (IND) is a request for authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans. Such authorization must be secured prior to interstate shipment and administration of any new drug or biological product that is not the subject of an approved New Drug Application or Biologics/Product License Application.

Emergency Use IND Requests
  • For investigational biological products regulated by CBER, call 301-827-2000
  • For all other investigational drugs, call 301-827-4570
  • After working hours, call FDA's Office of Emergency Operations at 301-443-1240
-

Training

  • FDA Clinical Investigator Training Course Exit Disclaimer
    Co-sponsored by FDA's Office of Critical Path Programs and the Clinical Trials Transformation Initiative (CTTI), with support from the National Institutes of Health
-
 

Contact Us

  • (800) 835-4709
  • (301) 827-1800
  • Consumer Affairs Branch (CBER)

    Division of Communication and Consumer Affairs

    Office of Communication, Outreach and Development

    Food and Drug Administration

    1401 Rockville Pike

    Suite 200N/HFM-47

    Rockville, MD 20852-1448

-
-
-
-
-
-